Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.51 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 3/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.47 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173862 | 0.89 | ABCG2 (0.62) | ADORA3SLC22A2SLC22A1PPARGABCG2 | |
| SCHEMBL3191617 | 0.83 | PPARG (0.70) | PPARGABCG2ABCB1KDM4EMEN1 | |
| SCHEMBL3181661 | 0.83 | CYP3A4 (0.62) | ADORA3ABCG2ABCB1ABCC1KDM4E | |
| SCHEMBL3184968 | 0.76 | PPARG (0.62) | PPARGABCG2ABCB1KDM4EMEN1 | |
| SCHEMBL29706587 | 0.76 | CYP3A4 (0.53) | ADORA3SLC22A2SLC22A1PPARGPTPN1 | |
| SCHEMBL3191656 | 0.74 | PDE5A (0.66) | PTPN1ABCG2ABCB1KDM4ECYP3A4 | |
| SCHEMBL28616504 | 0.74 | TP53 (0.44) | PPARGABCG2ABCB1KDM4EMEN1 | |
| SCHEMBL3173948 | 0.72 | ABCG2 (0.80) | ABCG2ABCB1ABCC1KDM4EMEN1 | |
| SCHEMBL17656837 | 0.72 | PLG (0.79) | ABCG2ABCB1ABCC1KDM4EMEN1 | |
| SCHEMBL29397591 | 0.71 | ABCG2 (0.74) | ADORA3SLC22A2SLC22A1PPARGABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262366-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | Shenogen Pharma Group Ltd. (CN) | 2010-12-22 | — | — | EP | disclosed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| WO-2009129372-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | ESR2, ESR1, ESRRB | ADORA3 1666/4885SLC22A2 2344/4885SLC22A1 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.